Dentsply Sirona Beats Q2 EPS at $0.52 and Reaffirms FY26 Sales Outlook
Question
Dentsply Sirona Beats Q2 EPS at $0.52 and Reaffirms FY26 Sales Outlook
Direct answer
DENTSPLY SIRONA (XRAY) posted second-quarter adjusted EPS of $0.52, outperforming the $0.36 consensus forecast despite a 4.1% year-over-year decline in overall revenue. Operational strength in the Wellspect Healthcare segment, which expanded 7.1%, helped mitigate dental equipment demand pressure. The company reaffirmed full-year 2026 guidance, targeting net sales between $3.5 billion and $3.6 billion alongside adjusted EPS of $1.40 to $1.50, demonstrating cost discipline amid uneven European and North American dental consumable volumes. — bullish pressure on XRAY.
- Original publisher
- Market Ontology
- Evidence through
- 2026-09-09
- Published
- 2026-10-20
- Revision
- 1 · 2026-10-20
Cite as: Market Ontology, “Dentsply Sirona Beats Q2 EPS at $0.52 and Reaffirms FY26 Sales Outlook”, revision 1, evidence through 2026-09-09. https://marketontology.com/catalysts/2026-09-09/dentsply-sirona-beats-q2-eps-at-0-52-and-reaffirms-fy26-sales-outlook-581f91
| Asset | Direction | Timeframe | Channel | Score |
|---|---|---|---|---|
| XRAY | ▲Bull | 1–5 days | Catalyst Driven | 63 |
Dentsply Sirona Beats Q2 EPS at $0.52 and Reaffirms FY26 Sales Outlook
DENTSPLY SIRONA (XRAY) posted second-quarter adjusted EPS of $0.52, outperforming the $0.36 consensus forecast despite a 4.1% year-over-year decline in overall revenue. Operational strength in the Wellspect Healthcare segment, which expanded 7.1%, helped mitigate dental equipment demand pressure. The company reaffirmed full-year 2026 guidance, targeting net sales between $3.5 billion and $3.6 billion alongside adjusted EPS of $1.40 to $1.50, demonstrating cost discipline amid uneven European and North American dental consumable volumes. — bullish pressure on XRAY.
DENTSPLY SIRONA (XRAY) posted second-quarter adjusted EPS of $0.52, outperforming the $0.36 consensus forecast despite a 4.1% year-over-year decline in overall revenue. Operational strength in the Wellspect Healthcare segment, which expanded 7.1%, helped mitigate dental equipment demand pressure. The company reaffirmed full-year 2026 guidance, targeting net sales between $3.5 billion and $3.6 billion alongside adjusted EPS of $1.40 to $1.50, demonstrating cost discipline amid uneven European and North American dental consumable volumes.
- SummaryDENTSPLY SIRONA (XRAY) posted second-quarter adjusted EPS of $0.52, outperforming the $0.36 consensus forecast despite a 4.1% year-over-year decline in overall revenue. Operational strength in the Wellspect Healthcare segment, which expanded 7.1%, helped mitigate dental equipment demand pressure. The company reaffirmed full-year 2026 guidance, targeting net sales between $3.5 billion and $3.6 billion alongside adjusted EPS of $1.40 to $1.50, demonstrating cost discipline amid uneven European and North American dental consumable volumes.
- XRAYDirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- XRAY closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- XRAY price vs. pre-event level
- XRAY volume vs. 20-day average
What happened next
| Asset | Call | Base close | +1 day | +5 days | +20 days |
|---|---|---|---|---|---|
| XRAY | Bullishdisagreed | 10.72 2026-09-09 | -2.05% | -5.41% | Pending |
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
No verifiable public source recorded for this card.
Related catalysts
- 2026-09-09Dentsply Sirona Beats Q2 EPS at $0.52 vs $0.36 Consensus and Affirms FY26 OutlookALGN XRAY-5.41%
- 2026-09-09Dentsply Sirona Beats Q2 EPS at $0.52 and Affirms FY2026 Sales GuidanceALGN XRAY-5.41%
- 2026-09-09Dentsply Sirona Tops Q2 EPS at $0.52 vs $0.36 Consensus and Affirms FY2026 GuidanceALGN XRAY-5.41%
- 2026-09-09Dentsply Sirona Beats Q2 EPS Estimates at $0.52 and Reaffirms FY2026 TargetsXRAY-5.41%
- 2026-09-09Dentsply Sirona Beats Q2 EPS at $0.52 and Reaffirms FY26 Sales OutlookXRAY-5.41%
- 2026-09-09Dentsply Sirona reports Q2 adjusted EPS of $0.52 and maintains $3.5B-$3.6B sales outlookALGN XRAY-5.41%
- 2026-09-09Dentsply Sirona Q2 EPS Beats at $0.52 Despite 4.1% Revenue ContractionXRAY-5.41%
- 2026-09-09Dentsply Sirona Beats Q2 EPS at $0.52 and Reaffirms FY26 Sales OutlookXRAY-5.41%
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.